


## DL-Buthionine-(S,R)-sulfoximine hydrochloride

**Cat. No.:** HY-106376B  
**Molecular Formula:** C<sub>8</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub>S  
**Molecular Weight:** 258.77  
**Target:** Ferroptosis  
**Pathway:** Apoptosis  
**Storage:** -20°C, sealed storage, away from moisture and light  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



H-Cl

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (386.44 mM; Need ultrasonic)					
	DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		3.8644 mL	19.3222 mL	38.6444 mL
<b>5 mM</b>			0.7729 mL	3.8644 mL	7.7289 mL	
	<b>10 mM</b>		0.3864 mL	1.9322 mL	3.8644 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (386.44 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
<b>IC<sub>50</sub> &amp; Target</b>	Glutamylcysteine synthetase <sup>[1]</sup>
<b>In Vitro</b>	Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous i.v infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95 % reduction in GSH tumor levels in both parental and multidrug-resistant tumors <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Adv Sci (Weinh). 2023 Jun 17;e2206798.
- Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123.
- Small. 2021 Nov 1;e2103984.
- Ecotoxicol Environ Saf. 2022 Dec 1;247:114263.
- Ecotoxicol Environ Saf. 2022, 247: 114263.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558-60.

[2]. Vanhoefer U, et al. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2(12):1961-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA